Fortitude Family Office’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$42.1K Buy
80
+45
+129% +$25.2K 0.01% 321
2026
Q1
$19.7K Buy
35
+5
+17% +$3.21K ﹤0.01% 433
2025
Q4
$20.3K Sell
30
-1
-3% -$681 ﹤0.01% 398
2025
Q3
$19.8K Buy
31
+1
+3% +$607 0.01% 393
2025
Q2
$16.1K Buy
30
+13
+76% +$6.22K 0.01% 424
2025
Q1
$7.14K Hold
17
﹤0.01% 631
2024
Q4
$7.03K Hold
17
﹤0.01% 739
2024
Q3
$8.59K Hold
17
﹤0.01% 609
2024
Q2
$8.28K Hold
17
﹤0.01% 451
2024
Q1
$9.18K Hold
17
0.01% 421
2023
Q4
$9.44K Buy
+17
New +$7.98K 0.01% 426

Other funds holding IDXX

Fortitude Family Office's IDXX Position: Q2 2026 in Review

Fortitude Family Office increased its Idexx Laboratories (IDXX) stake by 129% in Q2 2026, buying an estimated $25.2K and bringing the position to 80 shares worth $42.1K. The position accounts for 0.01% of the portfolio, ranked #321.

Fortitude Family Office first reported a position in IDXX in Q4 2023 and has held it in 11 quarters since. 1,295 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Fortitude Family Office held 80 shares of Idexx Laboratories worth $42.1K as of Q2 2026.
  • Fortitude Family Office bought 45 Idexx Laboratories shares in Q2 2026, an estimated $25.2K.
  • Idexx Laboratories made up 0.01% of Fortitude Family Office's portfolio in Q2 2026, its #321 holding.
  • Fortitude Family Office first reported a position in Idexx Laboratories in Q4 2023 and has held it in 11 quarters since.
  • 1,295 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.